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Background: To evaluate in-silico the performance of a model-based optimization process for volumetric
modulated arc therapy (RapidArc) applied to hepatocellular cancer treatments.
Patients and methods: 45 clinically accepted RA plans were selected to train a knowledge-based engine for the
prediction of individualized dose-volume constraints. The model was validated on the same plans used for training
(closed-loop) and on a set of other 25 plans not used for the training (open-loop). Dose prescription, target size,
localization in the liver and arc configuration were highly variable in both sets to appraise the power of
generalization of the engine. Quantitative dose volume histogram analysis was performed as well as a pass-fail
analysis against a set of 8 clinical dose-volume objectives to appraise the quality of the new plans.
Results: Qualitative and quantitative equivalence was observed between the clinical and the test plans. The use of
model-based optimization lead to a net improvement in the pass-rate of the clinical objectives compared to the
plans originally optimized with standard methods (this pass-rate is the frequency of cases where the objectives are
respected vs. the cases where constraints are not fulfilled). The increase in the pass-rate resulted of 2.0%, 0.9% and
0.5% in a closed-loop and two different open-loop validation experiments.
Conclusions: A knowledge-based engine for the optimization of RapidArc plans was tested and lead to clinically
acceptable plans in the case of hepatocellular cancer radiotherapy. More studies are needed before a broad clinical use.
Keywords: Knowledge based planning, RapidPlan, RapidArc, Liver cancerBackground
The radiation-oncology treatment planning process, is a
step where many information shall merge leading to the
most appropriate technique and dose distribution for all
individual patients. Different levels of “knowledge” contrib-
ute to decision making. The determination of the appropri-
ate dose-volume constraints is a problem that could be
“modeled” if the “features” causing inter-patient variability
could be converted into mathematical methods. These fea-
tures include the geometric, anatomical and dosimetric
characteristics of the treatment plans. The group of the
Duke University developed so-called knowledge-based* Correspondence: afc@iosi.ch
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unless otherwise stated.methods to solve this and applied them to clinical experi-
ments and to inter-institutional validation [1-5]. The
Washington University group developed similar architec-
tures to appraise the quality of treatment plans and to pre-
dict appropriate dose-volume constraints [6,7]. Others
focused on the possibility to automate the optimization
process and to test this in-silico or in clinical trials with
the final aim to develop data-driven, machine-based sys-
tems supporting the human clinical decision [8-14].
Aim of the present study is the evaluation of a
knowledge-based dose-volume constraints prediction en-
gine recently implemented in a commercial treatment plan-
ning system (TPS) partially based on the investigations of
the Duke’s group and further developed. The questions to
be addressed were: i) can such a predictive model be built
and lead to acceptable results for a real clinical problem? ii)l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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training patients? iii) can the model be reliable when no
special selection criteria are applied to generate the train-
ing, i.e. including cases with the only requirement to be
clinically acceptable?.
The case of advanced stage hepatocellular carcinoma
(HCC) was chosen (high variability in tumor size and pos-
ition in the liver). All the investigation was performed in
the arena of volumetric modulated arc therapy (VMAT).
Material and methods
The knowledge-based environment
A new optimization engine was introduced in the Eclipse
TPS (Varian Medical Systems, Palo Alto, USA) in the re-
lease 13.5. This is made of three main components: a model
building and training engine; a model-based dose-volume
histogram (DVH) and automated constraints prediction
tool; a new VMAT and IMRT optimization algorithm to
manage the above.
The sequence of main steps necessary to generate a
model is as follows:
– Selection of a set of training plans. No specific
requirements are mandatory to be candidate for
training. The strategy adopted was to create a
“universal” model for HCC and the only requirement
was to select plans accepted for clinical treatment.
– Association of these plans to a model layout where
target and organs at risk ontology, dose prescriptions
and some descriptive elements can be defined.
– Definition of the type of constraints to be generated
per each structure (points vs. lines, priorities, user
defined vs. fully automated).
– Dosimetric and geometrical data extraction from the
patient database to the model engine.
– Model training. Based on principal component (PC)
analysis methods [2,3,15,16].
– Model publication and validation.
Figure 1 shows a schematic representation of the model
determination steps and of the PC method applied to
DVH. The assumption is that any DVH can be repre-
sented as a combination of the average DVH over a popu-
lation plus a sum of some weighted PC and a residual.
The first PC is determined by maximizing the variance of
the training set it can explain; any consecutive PC is
chosen so that the residual variance is further accounted
for. The features used to build the model primarily include
geometric characteristic of the various structures, as well
as their mutual position and their relationships with the
treatment fields. These are modeled by constructing a
Geometry-Based Expected Dose (GED) which evaluates
the distance between each structure and the target surface
by means of the amount of dose that each targetcontributes to an organ for the current field geometry.
The final prediction model is built as a combination of the
PC and regression techniques for the in-field region of any
OAR and a mean and standard deviation model on the
DVH fo the other OAR regions. The PC is applied to the
GED and DVH to find the main component scores.
A trained model, once made “public”, can be used to
perform predictive estimation of the DVHs for any given
new test case and, from these, to determine the planning
constraints. The DVH prediction workflow is described as:
– Selection of a knowledge-based model
– Matching of structure names if the ontology
mapping is not complete
– Prediction of a range of possible DVH for each of the
structures present in both the plan and the model.
– Automatic generation of the dose-volume constraints
based on the rules from the model configuration.
With a fully automatic procedure, these are located
below the lower limit of a prediction range generated
from the most probable DVH curve by adding and
subtracting a variation curve. This corresponds to 1
standard deviation for the out-of-field region. For
the in-field region this is constructed by adding in
quadrature the DVH PC multiplied by the standard
error related to the model regression. Also the
priorities are defined by the prediction engine and
account for a basic balance between all possible
trade-offs. All point constraints and priorities can
be modified during optimization.
Figure 2 exemplifies the resulting model-based
predictive objectives with the estimate range and
automatic objectives (line objectives in this example).Patient selection
A group of 145 HCC patients was identified for the study.
All patients were managed in compliance with the Helsinki
Declaration. Ethical approval for retrospective and in-silico
studies was obtained by the institute’s ethical committee
and patients provided their consent for data manipulation.
RapidArc plans were approved and used for clinical treat-
ment of each patient. Details of plans and treatment out-
come have been described in detail in [17-19]. From this
library, 45 patients were selected for the model training
and other 25 were used for the validation experiments.
The selection of the two groups was done to proportionally
represent the dose prescription levels and the target vol-
umes observed in the main population. Concerning the
dose, the patients were chosen as follows: 55% with 60 Gy
or more, 50% with 40-45 Gy and 5% with less than 40 Gy;
in all cases the dose was prescribed at 2Gy/fractions. Target
volume was chosen uniformly though the range of the
population. Average target volume was 596 ± 538 cm3


















Figure 1 A schematic representation of the model determination steps and of the PC method applied to DVH.
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teria were applied. The number of partial arcs used for the
clinical plans ranged from 2 to 4 and non-coplanar setting
was applied for at least one arc in 40/45 cases in the
model-set and in 23/25 of the test cases. All plans used for
the training and for the validation phases were accepted
and used for treatment.Validation experiments
The system produces a summary about the training
process with some quality metrics. In the results, the
model goodness of estimation will be reported. This is the
mean squared error between original and estimate data
from a built-in cross validation where the training set is di-
vided in 10 parts; 10 models are trained and each model is
tested against a different tenth of the data points that are
left-out. The average of the validation statistics generated
during the 10 rounds is reported and helps to evaluate
how the model is able to estimate plans not used in the
training. The regression model’s parameters average chi
square measures the quality of the regression model. This
value is linked to the Pearson’s chi square and is measured
from the residual difference between the original data andthe estimation. The closer to one the value the better is
the quality of the regression model.
The whole estimation model’s fit describes how well
the estimation model represents the training plans in
the regression line. Results proximal to 1 suggest better
quality.
The training report includes also information about the
structures or patients that are found to be potential out-
liers based on some numerical metrics. In principle, struc-
tures can be identified as outliers if they significantly differ
in contouring or in dose features from the rest of the
population. Each candidate should be analyzed individu-
ally and, if judged truly different from the population,
might be excluded from the training set.
Cases candidate to be outlier in a model can be basic-
ally of two different types: geometric or dosimetric. In
geometric potential outliers, the structure contours sig-
nificantly differ from the rest of the population and
might indicate the use of different contouring protocols
or even more basic issues. In dosimetric potential out-
liers, the dose trade-offs are significantly different from
the rest of the population. This might indicate different
planning strategies (or techniques), different accept-
ance criteria or, even, presence of sub-optimal plans.
Figure 2 Examples of the model-based predictive objectives with the estimate range and automatic objectives (line objectives in
this example).
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to quantify the presence of potential outlieres. Among
these, the Cook’s distance (a standard statistical tool) sug-
gests the presence of highly influencial points in the re-
gression and suggests the need of careful evaluation of the
data. Reporting threshold have been set to 4. The studen-
tized residual describes the difference between actual and
estimated parameters for individual training cases. The
metrics is normalized by dividing the residuals by standard
deviation. In addition studentized residual tries to take ac-
count that for more influential points, smaller residual is
significant because the case has larger power to turn the
residual towards itself.
Three sets of validation experiments were conducted:
i) Closed-loop: re-optimization of the 45 training cases
using as optimization constraints the DVH estimated
by the model. Aim of this phase is to understand if
the prediction tool is capable to guarantee the same
clinical quality of plans for the same cases used to
build it. A positive validation is a pre-requisite.
ii) Open-loop I: optimization of the 25 test cases
using the model-predicted DVH for the same beam
geometry settings used for the clinical plans. A
positive validation implies the capability of the
prediction tool to generalize to un-known cases
presented with a geometrical plan setting
consistent with the training.
iii)Open-loop II: optimization of the 25 test cases using
a simpler arrangement with 2 coplanar partial arcs.A positive validation implies the further capability of
the system to generalize the DVH prediction when
the geometry of the arcs is different from what used
for the training.
During the interactive phase of the optimization
process, only the objective’s priorities were adjusted
if judged needed to better balance between them.
The starting point of the priorities was given by the
model prediction. This did not affected the
optimization time (no pauses were introduced) and
was performed only if some of the structures were
not responding or were too far from the constraints.
In all cases the Acuros-XB photon dose calculation
algorithm (v. 13.5) was applied with a dose matrix
resolution of 2.5 mm. All plans were normalized
to the mean dose to PTV as per institutional policy
in clinical routine and in compliance to ICRU
recommendations. Standard DVH quantitative
analysis was performed to appraise the quality of
the model-based optimized plans versus the
clinically accepted plans. A total of 8 dose-volume
endpoints were analyzed for each of the two groups
of patients for target volume (PTV) and organs at
risk (OAR). These were equal to what used for the
clinical acceptance of the original plans and
included: D1cm3 < 45 Gy to the spine, V15Gy < 35%
for both kidneys, V36Gy < 5% for the stomach, D1cm3 <
60 Gy and V55Gy < 30% for the esophagus, V30Gy < 30%
for the normal liver (liver-PTV) and D98% > 90% for
the PTV.
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Figure 3 shows the DVH for the population of 45 train-
ing patients for the PTV and different OARs. It is evi-
dent the large variance in the dataset. Figure 4 shows
the scatter plots of the DVH first PC vs. the correspond-
ing estimated one for some OARs; lines represents 1 SD.
Narrow distributions correlate to better quality of the
prediction power of the model. Points falling outside the
lines might be outlier candidates. The time needed to
extract the data to the model (dose distributions, geo-
metric data for the beams and structure volume infor-
mation) was about 10-15 seconds per patient. Model
training took less than 2 minutes. The total mean model
goodness of estimation (the mean squared error of the
residuals) resulted 0.007 ± 0.005. Table 1 presents some
of the training quality metrics from the system report.
For some of the structures, the complexity of the prob-
lem would have required more cases although the esti-
mation fit and the mean squared error between original
and estimated data do not reflect this problem. The ideal
number of cases is estimated by the training engine toNormal liver
Stomach
PTV
Figure 3 The DVH for the population of 45 training patients for the Pbe roughly equal to 5 times the number of parameters
used for the regression model. An insufficient number of
cases does not imply automatically a failure in the train-
ing but should be evaluated in relation to the quality of
the validation. Table 2 reports some details about the
number of candidate outliers per structure and the aver-
age of the pertinent metrics. The majority of cases iden-
tified as potential outliers presented a high Cook’s
distance, i.e. have high influence in the determination of
the regression coefficient. In a limited number of cases
(12), some outliers presented also a large studentized
residual value, this is a metric indicating that for more
influential points, even small residuals are significant in
the regression. Both categories do not suggest that the
cases should be rejected but that might deserve some
consideration if the validation of the model would fail.
All cases were individually analyzed and none resulted
characterized by evident errors or discrepancies with re-
spect to the clinical protocol applied for treatment.
Rather, the great variation in target shape and position
























Estimated DVH principal component score 1
Figure 4 Scatter plot and regression lines for some of the various principal-component analysis.
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dence of remarkably different cases but rather some
“uniform” dispersion of the data over the range. This
was one of the reasons to keep all potential outliers in









Small bowel 39 - 1
Left kidney 45 - 1
Right kidney 45 - 1
Left lung 35 60 1
Right lung 35 54 1
Esophagus 21 30 1
Normal liver 45 - 1
Spinal cord 45 - 1
Stomach 24 42 1
MSE mean squared error.Figure 5 shows the average DVHs for the PTV and
OARs for the clinical and for the re-optimized cases in
the close-loop while Figure 6 shows the same for the 2
open-loop validations. DVH for the PTV are shown in %
















Table 2 Analysis of outliers
Organ Number of structures in the model Number of potential outliers Reason Average score
Small bowel 39 5
Cook’s distance: 5 11.5 ± 8.9
SSR: 2 4.1 ± 0.9
Left kidney 45 9
Cook’s distance: 9 11.5 ± 6.1
SSR: 4 4.0 ± 0.6
Right kidney 45 1 Cook’s distance: 1 4.6
Left lung 35 19 Cook’s distance: 19 19.1 ± 13.2
Right lung 35 13
Cook’s distance: 12 7.9 ± 5.7
SSR: 3 4.0 ± 1.4
Esophagus 21 6
Cook’s distance: 2 5.3 ± 0.6
SSR: 6 3.7 ± 0.8
Normal liver 45 7 Cook’s distance: 7 11.2 ± 9.3
Spinal cord 45 6
Cook’s distance: 6 8.2 ± 2.8
SSR: 2 3.4 ± 0.0
Stomach 24 6
Cook’s distance: 3 6.5 ± 2.9
SSR: 4 3.3 ± 0.5





Figure 5 Average DVH for the closed-loop validation experiment. The Orig lines are for the clinical plans while the Test lines for the
model-based optimization.
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both clinical and test plans, with some limited individual
violations. Model-based plans resulted on average im-
proved with respect to the clinical cases, and the max-
imum value in the ranges is always higher for clinical
than for test plans. Table 4 further expands the report
on DVH analysis. Figure 7 shows the axial isodose distri-
butions for 3 examples from the open-loop validation.
The time needed to generate the estimated DVH for the
test cases was about 15 seconds.
Table 5 reports the values of the parameters that were
violated either in the clinical or in the test plans.
Closed-loop validation
Of the 360 dose-volume points analyzed (8 parameters for
45 patients), 11 points (3.1%) in 7 patients violated the con-
straints in the original clinical dataset; one patient had 4
simultaneous violations. Only 4 points (1.1%) in 3 patients
failed to respect the objectives in the test set (and only 2
simultaneous violations in 1 patient). All 4 failures in the
validation phase were also failures in the clinical plans.
Open-loop validation I
9 of 224 dose-volume points (4.0%, 9 patients, 1 failure
per patient, 6 in the right kidney and 3 in the healthy liver)PTV
Right Kidney
Figure 6 Average DVH for the two open-loop validation experiments
model-based optimization with the same non-coplanar geometry, and thefailed to respect the constraints in the clinical dataset of
25 patients. This number was reduced to 6 failures (2.7%)
in the model-based plans. Of these 3 (2 in the right kidney,
2 in the healthy liver) were already present in the clinical
plans while 3 new failures (2 on the same patient) were
observed in the right kidney and D98% to the PTV (89.3%
instead of 94.8% of the test clinical plan and 90% of the
objective).
Open-loop validation II
Only 4 of 224 dose-volume points (1.8%) failed in the
test group (against the same 9 described above) in 4 pa-
tients. Three in the healthy liver and one in the D98% to
the PTV (89.8% instead of the 94.8% of the clinical and
90% of the objective).
Despite this was not a primary objective of the study,
the net improvement in passing the clinical objectives
for the model-based plans resulted modest in the three
experiments (2.0%, 0.9%, 0.5%).
Discussion
Good et al [5] applied knowledge-based methods to the
IMRT planning of prostate. The results showed improved
target homogeneity, sparing of OARs and superior or
equivalent plans in 95% of the cases when compared toLiver-PTVEsophagus
Stomach
Spinal Cord 
. The Orig lines are for the clinical plans, the Test lines for the
Test_2 lines for the simplified, coplanar only arc setting.
Table 3 Summary the DVH analysis for the clinical cases of the closed-loop and the two open-loop validations
Model validation on the training set of 45 patients Objective Clinical plans Closed-loop validation p
PTV: V98% [%] >90%
97.2 ± 0.9 96.8 ± 1.4
- NS
[94.9-98.9] [91.4-98.7]
Normal liver: V30Gy [%] <30%
14.7 ± 11.4 14.2 ± 9.6
- NS
[0.0-51.4] [0.0-36.8]
Spine: D1cm3 [Gy] <45 Gy
15.6 ± 8.0 15.1 ± 9.0
- <0.05
[3.9-45.3] [2.7-40.4]
Left kidney V15Gy [%] <35%
1.3 ± 6.2 0.6 ± 2.6
- <0.01
[0.0-39.2] [0.0-14.6]
Right kidney V15Gy [%] <35%
14.3 ± 17.8 8.1 ± 10.8
- <0.01
[0.0-77.4] [0.0-39.9]
Stomach V35Gy [%] <5%
0.1 ± 0.7 0.1 ± 0.6
- NS
[0.0–3.3] [0.0-2.8]
Esophagus: D1cm3 [Gy] <60 Gy
25.4 ± 8.5 23.4 ± 8.7
- <0.10
[12.5-39.9] [10.4-37.4]
Esophagus: V30Gy [%] <30%
0.0 ± 0.0 0.0 ± 0.0
- NS
[0.0-0.0] [0.0-0.0]
Validation on the independent sample of 25 patients Objective Clinical plans Open-loop Validation I Open-loop Validation II
PTV: V98% [%] >90%
97.4 ± 0.9 96.8 ± 1.9 97.1 ± 2.6 I: <0.05
[94.9-98.3] [89.3-98.3] [89.8-98.6] II: NS
Normal Liver: V30Gy [%] <30%
16.2 ± 10.3 16.9 ± 9.9 18.0 ± 10.5 I: <0.05
[0.0-36.3] [0.0-35.1] [0.0-39.5] II: <0.01
Spine: D1cm3 [Gy] <45 Gy
18.7 ± 7.4 17.6 ± 8.2 15.1 ± 5.5 I: <0.01
[4.1-36.0] [4.3-37.2] [3.9-25.3] II: <0.01
Left kidney V15Gy [%] <35%
1.4 ± 4.3 0.3 ± 1.4 0.01 ± 0.05 I: <0.01
[0.0-19.6] [0.0-6.9] [0.0-0.3] II: <0.01
Right kidney V15Gy [%] <35%
17.6 ± 18.5 12.8 ± 15.0 10.3 ± 10.8 I: <0.01
[0.0-49.9] [0.0-39.7] [0.0-34.4] II: <0.01
Stomach V35Gy [%] <5%
0.1 ± 0.3 0.3 ± 1.0 0.0 ± 0.0 I: <0.04
[0.0-0.8] [0.0-4.2] [0.0-0.0] II: NS
Esophagus: D1cm3 [Gy] <60 Gy
25.7 ± 9.6 21.9 ± 9.8 17.3 ± 4.7 I: <0.01
[11.9-46.9] [0.5-46.1] [10.8-25.1] II: <0.01
Esophagus: V30Gy [%] <30%
0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 I: NS
[0.0-0.0] [0.0-0.0] [0.0-0.0] II: NS
VxGy Volume receiving at least XGy, DY% (Dycm3) dose delivered to at least Y% (or cm
3) of the volume. NS not significant. I: clinical vs. Open-loop I; II: clinical vs. Open-loop II.
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to transfer the planning knowledge from a more to a less
experienced institute. Moore et al [6] showed improved
plan quality, reduced inter-clinician variability and sug-
gested that the automatic tools might be used as a quality
assurance method for IMRT planning.
The scope of the present study was to appraise the
possibility to use a knowledge-based dose-constraint
prediction methodology with clinically acceptable re-
sults. No special efforts were put to analyze in detail thealgorithms which are not fully accessible to the investi-
gators. The results obtained for HCC and RapidArc
support the conclusion that, even in the case of a rela-
tively ill-defined problem, it was possible to train a
dose-volume constraints prediction model with a lim-
ited number of patients.
The “ill-defined” condition derived from the variability
of tumor sizes, localization in the liver and dose pre-
scriptions resulting in a very large variance of the input
data. This was confirmed by the number of outlier
Table 4 Integration of the summary the DVH analysis for the clinical cases of the two open-loop validations
Validation on the independent sample of 25 patients Clinical plans Open-loop validation I Open-loop validation II p
PTV: Mean [%]
100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 I: NS
[0.0-0.0] [0.0-0.0] [0.0-0.0] II: NS
PTV: D1% [%]
106.8 ± 2.4 107.6 ± 2.3 105.4 ± 1.0 I:<0.05
[103.5-114.3] [104.3-112.6] [103.1-107.0] II:<0.05
PTV: D99% [%]
90.0 ± 2.5 90.2 ± 3.7 92.8 ± 3.8 I:NS
[82.6-93.5] [79.4-94.8] [80.4-95.9] II:<0.05
PTV: HI
0.13 ± 0.04 0.12 ± 0.04 0.08 ± 0.02 I:NS
[0.07-0.23] [0.06-0.20] [0.05-0.15] II:<0.01
PTV: CI
1.11 ± 0.07 1.08 ± 0.05 1.05 ± 0.04 I:<0.05
[1.05-1.21] [1.01-1.13] [1.00-1.11] II:<0.01
Normal liver: Mean dose [Gy]
15.6 ± 5.5 15.4 ± 5.1 16.4 ± 5.4 I: NS
[5.8-23.5] [6.2-23.0] [6.9-23.8] II: <0.05
Spine: Mean dose [Gy]
9.2 ± 4.5 8.2 ± 4.9 6.6 ± 3.5 I: <0.05
[1.0-19.7] [0.9-19.9] [0.8-15.5] II: <0.01
Left kidney Mean dose [Gy]
3.9 ± 3.1 2.5 ± 2.1 2.0 ± 1.7 I: <0.01
[0.2-12.7] [0.2-9.2] [0.1-7.5] II: <0.01
Right kidney Mean dose [Gy]
7.9 ± 5.8 6.3 ± 4.8 5.6 ± 4.0 I: <0.01
[0.7-18.9] [0.6-14.6] [0.8-12.6] II: <0.01
Stomach Mean dose [Gy]
10.9 ± 2.9 9.2 ± 4.5 9.4 ± 3.5 I: <0.05
[5.8-16.1] [3.8-20.8] [3.6-15.9] II: <0.05
Esophagus: Mean dose [Gy]
17.8 ± 8.2 13.9 ± 7.4 10.9 ± 3.9 I: <0.05
[4.9-38.2] [3.8-34.1] [4.6-18.0] II: <0.01
Body-PTV: V10Gy [%]
17.1 ± 8.1 16.7 ± 7.9 16.8 ± 7.6 I: <0.10
[2.6-31.5] [2.6-32.9] [3.1-32.3] II: <0.10
For the PTV, conformity Index CI is defined as the ration between V95% and PTV. Homogeneity index HI is defined as (D5-D95)/Mean.
VxGy Volume receiving at least XGy, DY% (Dycm3) dose delivered to at least Y% (or cm
3) of the volume. CI Conformity Index, HI homogeneity Index, NS not
significant. I: clinical vs. Open-loop I; II: clinical vs. Open-loop II.
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dates were classified as influential points and were left
in the model after individual examination. Further stud-
ies will be needed to determine simple and pragmatic
methods to exclude those cases that could significantly
(and negatively) impact on the model prediction cap-
ability. To notice that the training validation report does
not identify the presence of “absolute” outliers but
points to the cases where one or more metrics results
out of some (arbitrary) threshold and would require fur-
ther investigation.
The model was built with 45 patients. It was out of
scope to determine what could be the minimum rea-
sonable sample size; further studies will address this
point. The manufacturer defined a minimum of 20 cases
necessary to build a model (in addition, if any given struc-
ture would not have at least 20 cases, no prediction model
would be provided for it). In addition, the end of training
report suggests a recommended number of cases per
structure (roughly estimated by the manufacturer to be 5times the parameters used for the regression model not
based on specific metrics). This last value is anyway not
mandatory to operate the system and the results suggest
that the training can be performed also starting from
smaller samples.
Concerning the proper validation, the experiments
proved that the model was capable to reproduce the
clinical data in both the closed-loop and open-loop vali-
dations. On average, model-based plans slightly im-
proved the clinical correspondents. To test the power of
generalization of the predictive engine, it was hypothe-
sized that the beam arrangement might be a limiting fac-
tor. The results obtained from the open-loop validation
II improved the results of the clinical and open-loop I
plans. This might be due to external factors including
that the non-coplanar setting was not mandatory with
the latest version of the optimizer.
The assessment of the quality of the original beam ar-
rangement wasn’t part of the scope of the study but,
while it was part of it the investigation of the model
Clinical Model-based
Figure 7 Shows the axial isodose distributions for 3 examples from the open-loop validation.
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http://www.ro-journal.com/content/9/1/236robustness to different conditions. As a side effect the
data resulted preferable (even if the improvement would
likely be not clinically relevant). Within the limits of the
study and with the need of further proof, these findings
might suggest that the model-based optimization engine
might be insensitive to some extent to the geometry
chosen, provided that the latter is anyway appropriate.
Since, in an inverse planning environment, many differ-
ent beam arrangement could lead to similar dose distri-
butions through optimization, this result is reasonable.
What observed suggests also the possibility to intro-
duce feed-back loops in the training. The idea would be
to replace original training plans with the model-based
improved ones and to re-train the model. This might
lead to a tightening of the prediction ranges and was
proven by the Duke and Washington University groups.
We omitted this possibility given the primary goal of
the study aiming to demonstrate the basic performance
of the system.A remark concerns the level of “automation” that can
be desirable in a model-based system. The predicted
dose-volume constraints are located at the lower limit
of the predicted range of the possible solutions for the
individual case. Priorities for the constraints are auto-
matically generated to guarantee a reasonable probabil-
ity of achieving the result but all is “constructed” before
the actual optimization is performed. It is still conceiv-
able that further improvements could be obtained and/
or some complex trade-off should be addressed. There-
fore some interactive adjustment of the parameters
might be necessary during optimization. In the present
study, only the optimization priorities were adjusted for
some of the constraints (mostly the maximum target
dose or less involved structures) and not all the patients.
Data are insufficient to conclude that this procedure is a
needed step. In the specific case, it proved to be benefi-
cial but might be that in simpler cases it would be
avoided. It was out of the scope of this study to present
Table 5 Patterns of planning constraints violations in the closed loop validation
Patient Parameter Clinical plan Closed-loop validation
1 Normal Liver V30Gy < 30% 31.7% 31.9% -
2 Normal Liver V30Gy < 30% 30.6% 29.4% -
3 Normal Liver V30Gy < 30% 34.8% 29.8% -
4 Spinal cord D1cm3 < 45Gy 45.3% 40.3% -
Left Kidney V15Gy < 35% 39.2% 14.6% -
Right kidney V15Gy < 35% 53.8% 39.9% -
Normal Liver V30Gy < 30% 51.4% 36.9% -
5 Right kidney V15Gy < 35% 77.4% 38.3% -
Normal Liver V30Gy < 30% 31.8% 23.3% -
6 Right kidney V15Gy < 35% 41.6% 19.4% -
7 Right kidney V15Gy < 35% 43.6% 26.7% -
Patient Parameter Clinical plan Open-loop validation I Open-loop validation II
1 Normal Liver V30Gy < 30% 30.5% 27.4% 30.6%
2 Right kidney V15Gy < 35% 46.9% 39.7% 23.6%
3 Right kidney V15Gy < 35% 38.5% 34.8% 34.4%
4 Normal Liver V30Gy < 30% 29.3% 31.0% 29.9%
5 Right kidney V15Gy < 35% 31.8% 36.9% 20.5%
6 Right kidney V15Gy < 35% 38.6% 36.6% 21.5%
PTV D98% > 90% 94.8% 89.3% 89.8%
7 Normal Liver V30Gy < 30% 32.1% 32.5% 33.1%
8 Normal Liver V30Gy < 30% 36.3% 30.0% 39.5%
9 Right kidney V15Gy < 35% 49.9% 26.9% 17.0%
10 Right kidney V15Gy < 35% 38.9% 26.5% 25.0%
11 Right kidney V15Gy < 35% 46.3% 25.6% 22.7%
In bold the parameters that were violated. The patients in the two groups are different.
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tweaked priorities, or to fine tune the priorities to set
for eventual additional constraints during the model
configuration.
The time needed to prepare a model or to generate
the constraints for individual patients was briefly ad-
dressed and resulted short. The time needed to prepare
an optimization and to execute it was not included in
the assessment since strongly dependent on the planner
skills and, for this reason not easy to objectively quan-
tify. On the other side, the pure optimization time, in
the absence of interactive intervention, is independent
from the method chosen to generate the dose-volume
constraints.
Conclusions
The construction and training of a knowledge-based
dose-volume constraints predictive model was tested
successfully for patients with HCC. The quality of the
RapidArc plans optimized using this method was con-
sistent compared to the treated plans. Although more
systematic studies are needed before a broad clinicalapplication of the methodology, the model-based
optimization strategy might be considered as a tool to
streamline and improve the planning process.
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